

# National Board of Examinations

<b>Question Paper Name :</b>	DrNB CLINICAL HAEMATOLOGY Paper1
<b>Subject Name :</b>	DrNB CLINICAL HAEMATOLOGY Paper1
<b>Creation Date :</b>	2023-10-15 14:11:35
<b>Duration :</b>	180
<b>Share Answer Key With Delivery Engine :</b>	No
<b>Actual Answer Key :</b>	No

## DrNB CLINICAL HAEMATOLOGY Paper1

<b>Group Number :</b>	1
<b>Group Id :</b>	3271872615
<b>Group Maximum Duration :</b>	0
<b>Group Minimum Duration :</b>	180
<b>Show Attended Group? :</b>	No
<b>Edit Attended Group? :</b>	No
<b>Group Marks :</b>	100
<b>Is this Group for Examiner? :</b>	No
<b>Examiner permission :</b>	Cant View
<b>Show Progress Bar? :</b>	No

## DrNB CLINICAL HAEMATOLOGY Paper1

<b>Section Id :</b>	3271872618
<b>Section Number :</b>	1
<b>Section type :</b>	Offline

<b>Mandatory or Optional :</b>	Mandatory
<b>Number of Questions to be attempted :</b>	10
<b>Section Marks :</b>	100
<b>Enable Mark as Answered Mark for Review and Clear Response :</b>	Yes
<b>Maximum Instruction Time :</b>	0
<b>Sub-Section Number :</b>	1
<b>Sub-Section Id :</b>	3271872622
<b>Question Shuffling Allowed :</b>	No
<b>Is Section Default? :</b>	null

**Question Number : 1 Question Id : 32718726834 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

**Please write your answers in the answer booklet within the allotted pages as follows:-**

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. a) Describe stages in B cell development. [3]
- b) Classify B cell lymphoma based on B cell development stages. [4]
- c) Describe role of BCL2 in lymphomagenesis. [3]

**Question Number : 2 Question Id : 32718726835 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

A primigravida is presented with platelet count of 30000/cumm during her third trimester:

- a) Describe clinical and laboratory approach to the patient. [4]

b) What are the differential diagnosis and how will you differentiate? [3]

c) How would you manage the above pregnant lady (after a diagnosis of primary immune thrombocytopenia is made) at the time of delivery? [3]

**Question Number : 3 Question Id : 32718726836 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

a) Describe cellular basis of immune tolerance post allogenic stem cell transplantation. [5]

b) Describe role of mesenchymal stem cells in management of post stem cell transplantation patient. [5]

**Question Number : 4 Question Id : 32718726837 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

a) Discuss Coombs' Negative Autoimmune Hemolytic Anemia (AIHA). [3]

b) Describe pathophysiology of cold (IgM mediated) agglutinin hemolytic anemia. [4]

c) How would you manage a patient with cold agglutinin hemolytic anemia? [3]

**Question Number : 5 Question Id : 32718726838 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

a) Describe the levels of evidences in research methodology. [3]

b) Describe role of randomisation in randomised control studies. [3]

c) Describe role of concealment (blinding) in randomised control studies. [4]

**Question Number : 6 Question Id : 32718726839 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Describe principles of thromboelastography (TEG) and its interpretation. [6]
- b) Describe scenarios where TEG is being used in clinical practice. [4]

**Question Number : 7 Question Id : 32718726840 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Describe the molecular basis of inherited platelet function defects. [5]
- b) Discuss in brief Glanzmann thrombosthenia. [5]

**Question Number : 8 Question Id : 32718726841 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Describe beta globin gene complex structure. [4]
- b) Describe the process of globin chain switch over (gamma to beta). [3]
- c) Describe potential therapeutic manipulations of globin chain switch. [3]

**Question Number : 9 Question Id : 32718726842 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Describe fate of B cells after being infected by Epstein Barr Virus (EBV). [3]
- b) Enumerate and describe B cell lymphoproliferative diseases associated with EBV. [3]
- c) Describe management of Post Transplantation Lymphoproliferative diseases. [4]

**Question Number : 10 Question Id : 32718726843 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

a) Describe genetic basis of ABO and Rh blood group. [4]

b) Describe management of immediate and delayed blood transfusion reactions. [6]